LONDON - Crystal Amber Fund Limited (LSE:CRS) has received approximately £18 million in final proceeds from the completed takeover of De La Rue (LON:DLAR) plc, according to a fund update released Friday. The payment follows the De La Rue scheme of arrangement becoming effective on July 2, bringing Crystal Amber’s total proceeds from the transaction to £40.67 million since De La Rue entered an offer period. The fund’s board is considering its future strategy and use of these proceeds, including potential capital returns to shareholders through its ongoing share buyback program and possible distributions. Crystal Amber is now focusing on its investment in Morphic Medical Inc. (MMI), which recently obtained CE Mark approval for its RESET device, allowing sales to begin in Germany with plans to expand across the European Union. The company expects UK approval through MHRA registration in the coming weeks. The RESET device is a minimally invasive, reversible implant that mimics gastric bypass surgery without permanently altering patient anatomy. The procedure takes approximately 20 minutes, with the device typically remaining in place for nine months before removal. MMI is currently recruiting patients for an FDA-approved pivotal study, with potential U.S. approval estimated for the second half of 2027. The company is in discussions with several potential investors, including an unnamed S&P 500 healthcare company that has expressed interest in investing $5-10 million. Crystal Amber has invested $5.15 million in MMI since the start of 2025 at $0.48 per share and anticipates investing up to an additional $1.5 million in the coming weeks. The fund currently owns approximately 96.7% of MMI’s combined issued common and preference shares. According to the press release, Crystal Amber is also seeking to maximize value from its other investments in Sigma Broking Limited, Allied Minds, and Sutton Harbour Plc. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Crystal Amber receives £18 million from De La Rue takeover
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...